Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

Broker’s call: Molbio Diagnostics (Buy)

Motilal Oswal

Broker’s call: Molbio Diagnostics (Buy)

Molbio Diagnostics, a diagnostics technology company, has been building its business around the Truenat platform, which is a portable molecular testing system enabling rapid point-of-care testing without extensive infrastructure. The company's devices are deployed in over 90 countries, with a substantial installed base of 12,500+ units.

The company offers an extensive range of 43 assays covering 30 different diseases, tapping into a global market for POCT infectious-disease testing valued at $9.3 billion and projected to grow at a compound annual growth rate (CAGR) of around 23%.

Molbio's strategic advantage lies in its integrated Truenat ecosystem, which merges proprietary molecular diagnostic devices with a recurring test-kit franchise. This integrated approach allows the company to capture the expanding market of decentralized molecular diagnostics. The company's expansion is driven by three key factors: its growing installed base of Truenat devices, the increasing number of assays, and global scale-up efforts.

Additionally, as the company's utilization rate improves, operating leverage is expected to increase. Based on these projections, the analyst forecasts a 23% revenue CAGR, a 910 basis points margin expansion, and a 50% CAGR in the PAT market over the FY26-29 fiscal years.

The target price for Molbio Diagnostics is estimated at ₹1,800, calculated using a 45x 12-month forward earnings multiple. The analyst initiates coverage of Molbio with a Buy rating. However, there are certain risks associated with the company, such as customer concentration, the high revenue contribution of TB testing, potential delays in regulatory approvals, and slower-than-expected adoption of Truenat technology.

Rewritten by urgent.news; may contain errors — check the original.

Read the original at thehindubusinessline.com →

Report a problem with this story

More in Finance & Markets

More from Wednesday 7 October →